The Europe Radiotherapy Market is expected to witness market growth of 6.0% CAGR during the forecast period (2022-2028).
It might, however, have protons or, less frequently, electrons. Ionizing high-energy radiation used in radiotherapy damages the DNA of the cancer cells in the surgical site, eliminating them. Normal cells are also impacted by radiation. Side effects in the treatment zone may result from this. Typically, adverse symptoms subside a few weeks following therapy, although some may last for a while. Most frequently, external beam radiation therapy is indicated when the phrase radiation therapy is used. The high-energy beams used in this form of radiation originate from a device outside of the body and are directed at a specific location on the body. Radiation is injected inside the body during brachytherapy, a new kind of radiation therapy.
Radiation therapy harms cells by eradicating the genetic material that regulates cell division and growth. Radiation therapy damages both healthy and cancerous cells, but its objective is to kill as few healthy and normal cells as possible. The majority of radiation-induced damage can frequently be repaired by normal cells. A linear accelerator, which sends high-energy radiation beams into the body, is typically used to deliver external beam radiation therapy. The linear accelerator moves around the patient as they lay on the table, delivering radiation from various angles. The linear accelerator can be modified to give the precise radiation dose that the doctor has prescribed for specific circumstances.
One of the fundamental elements of interdisciplinary cancer care is radiation therapy. More than one in four cancer patients in Europe do not get the radiotherapy they require, despite the fact that around 50% of all cancer patients in Europe have at least one indication for it at some point during their illness. There are several causes for this underutilization, but a significant underlying factor for inadequate access to radiation is the scarcity of the requisite resources, including qualified personnel and equipment. Furthermore, significant differences in workload, as well as the availability of radiotherapy professionals and equipment per resident or each cancer patient in need of radiotherapy, are witnessed among European countries.
The Germany market dominated the Europe Radiotherapy Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $619.7 million by 2028. The UK market is anticipated to grow at a CAGR of 5.1% during (2022 - 2028). Additionally, The France market is expected to exhibit a CAGR of 6.7% during (2022 - 2028).
Based on End User, the market is segmented into Hospitals & Clinics and Others. Based on Type, the market is segmented into External Beam Radiation Therapy, Internal Radiation Therapy and Systemic Radiation Therapy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Becton, Dickinson and Company, Siemens Healthineers AG, Accuray, Incorporated, Elekta AB, Eckert & Ziegler AG, Ion Beam Applications SA, iCAD Inc., Isoray Inc., Mevion Medical Systems, Inc., and Nordion Inc. (Sotera Health LLC).
It might, however, have protons or, less frequently, electrons. Ionizing high-energy radiation used in radiotherapy damages the DNA of the cancer cells in the surgical site, eliminating them. Normal cells are also impacted by radiation. Side effects in the treatment zone may result from this. Typically, adverse symptoms subside a few weeks following therapy, although some may last for a while. Most frequently, external beam radiation therapy is indicated when the phrase radiation therapy is used. The high-energy beams used in this form of radiation originate from a device outside of the body and are directed at a specific location on the body. Radiation is injected inside the body during brachytherapy, a new kind of radiation therapy.
Radiation therapy harms cells by eradicating the genetic material that regulates cell division and growth. Radiation therapy damages both healthy and cancerous cells, but its objective is to kill as few healthy and normal cells as possible. The majority of radiation-induced damage can frequently be repaired by normal cells. A linear accelerator, which sends high-energy radiation beams into the body, is typically used to deliver external beam radiation therapy. The linear accelerator moves around the patient as they lay on the table, delivering radiation from various angles. The linear accelerator can be modified to give the precise radiation dose that the doctor has prescribed for specific circumstances.
One of the fundamental elements of interdisciplinary cancer care is radiation therapy. More than one in four cancer patients in Europe do not get the radiotherapy they require, despite the fact that around 50% of all cancer patients in Europe have at least one indication for it at some point during their illness. There are several causes for this underutilization, but a significant underlying factor for inadequate access to radiation is the scarcity of the requisite resources, including qualified personnel and equipment. Furthermore, significant differences in workload, as well as the availability of radiotherapy professionals and equipment per resident or each cancer patient in need of radiotherapy, are witnessed among European countries.
The Germany market dominated the Europe Radiotherapy Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $619.7 million by 2028. The UK market is anticipated to grow at a CAGR of 5.1% during (2022 - 2028). Additionally, The France market is expected to exhibit a CAGR of 6.7% during (2022 - 2028).
Based on End User, the market is segmented into Hospitals & Clinics and Others. Based on Type, the market is segmented into External Beam Radiation Therapy, Internal Radiation Therapy and Systemic Radiation Therapy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Becton, Dickinson and Company, Siemens Healthineers AG, Accuray, Incorporated, Elekta AB, Eckert & Ziegler AG, Ion Beam Applications SA, iCAD Inc., Isoray Inc., Mevion Medical Systems, Inc., and Nordion Inc. (Sotera Health LLC).
Scope of the Study
Market Segments Covered in the Report:
By End User
- Hospitals & Clinics
- Others
By Type
- External Beam Radiation Therapy
- Internal Radiation Therapy
- Systemic Radiation Therapy
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Becton, Dickinson and Company
- Siemens Healthineers AG
- Accuray, Incorporated
- Elekta AB
- Eckert & Ziegler AG
- Ion Beam Applications SA
- iCAD Inc.
- Isoray Inc.
- Mevion Medical Systems, Inc.
- Nordion Inc. (Sotera Health LLC)
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Europe Radiotherapy Market by End User
Chapter 5. Europe Radiotherapy Market by Type
Chapter 6. Europe Radiotherapy Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Becton, Dickinson and Company
- Siemens Healthineers AG
- Accuray, Incorporated
- Elekta AB
- Eckert & Ziegler AG
- Ion Beam Applications SA
- iCAD Inc.
- Isoray Inc.
- Mevion Medical Systems, Inc.
- Nordion Inc. (Sotera Health LLC)
Methodology
LOADING...
